Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2007-06-13
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 131
- Registration Number
- NCT00221624
- Locations
- 🇫🇷
Service d'hépato-Gastro-Entérologie - Hôpital Haut Leveque - avenue de Magellan, Pessac, France
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 896
- Registration Number
- NCT00192647
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-03-06
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00172809
- Locations
- 🇨🇳
National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2009-02-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 300
- Registration Number
- NCT00144469
Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 208
- Registration Number
- NCT00136318
- Locations
- 🇩🇪
Department of Gastroenterolgy and Rheumatology, Sektion Hepatology, Leipzig, Germany
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
- Conditions
- Interventions
- First Posted Date
- 2005-04-07
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 569
- Registration Number
- NCT00107653
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
- Conditions
- First Posted Date
- 2005-01-04
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 2
- Registration Number
- NCT00100581
- Locations
- 🇺🇸
Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States
🇺🇸Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas, Texas, United States
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive
- Conditions
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-06-22
- Lead Sponsor
- Bausch Health Americas, Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT00093093
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇨🇦Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2009-08-07
- Target Recruit Count
- 12
- Registration Number
- NCT00078442
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of California, Davis Medical Center, Sacramento, California, United States
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
- Conditions
- Interventions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2021-11-08
- Target Recruit Count
- 333
- Registration Number
- NCT00078403
- Locations
- 🇺🇸
Johns Hopkins University CRS, Baltimore, Maryland, United States
🇺🇸University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.